-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
19 Feb 2026
-
Net transactions value
-
-$19,133,829
-
Form type
-
4
-
Filing time
-
23 Feb 2026, 16:21:44 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Sachdev Amit |
EVP Chief Patient & Ext Af Off |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
23 Feb 2026 |
0001406338 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Options Exercise |
$3,652,628 |
+23,479 |
+34% |
$155.57 |
92,521 |
19 Feb 2026 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Options Exercise |
$4,693,126 |
+25,026 |
+27% |
$187.53 |
117,547 |
19 Feb 2026 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$426,797 |
-920 |
-0.78% |
$463.91 |
116,627 |
19 Feb 2026 |
Direct |
F1, F2, F3 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,269,586 |
-2,730 |
-2.3% |
$465.05 |
113,897 |
19 Feb 2026 |
Direct |
F1, F3, F4 |
| transaction |
VRTX |
Common Stock |
Sale |
$860,798 |
-1,848 |
-1.6% |
$465.80 |
112,049 |
19 Feb 2026 |
Direct |
F1, F3, F5 |
| transaction |
VRTX |
Common Stock |
Sale |
$4,800,518 |
-10,263 |
-9.2% |
$467.75 |
101,786 |
19 Feb 2026 |
Direct |
F1, F3, F6 |
| transaction |
VRTX |
Common Stock |
Sale |
$9,213,023 |
-19,662 |
-19% |
$468.57 |
82,124 |
19 Feb 2026 |
Direct |
F1, F3, F7 |
| transaction |
VRTX |
Common Stock |
Sale |
$3,400,446 |
-7,241 |
-8.8% |
$469.61 |
74,883 |
19 Feb 2026 |
Direct |
F1, F3, F8 |
| transaction |
VRTX |
Common Stock |
Sale |
$5,510,964 |
-11,712 |
-16% |
$470.54 |
63,171 |
19 Feb 2026 |
Direct |
F1, F3, F9 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,997,449 |
-4,237 |
-6.7% |
$471.43 |
58,934 |
19 Feb 2026 |
Direct |
F1, F3, F10 |
| holding |
VRTX |
Common Stock |
|
|
|
|
|
882 |
19 Feb 2026 |
401(k) |
|
| holding |
VRTX |
Common Stock |
|
|
|
|
|
9,301 |
19 Feb 2026 |
Held in Trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-23,479 |
-100% |
$0.000000 |
0 |
19 Feb 2026 |
Common Stock |
23,479 |
$155.57 |
Direct |
F11 |
| transaction |
VRTX |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-25,026 |
-100% |
$0.000000 |
0 |
19 Feb 2026 |
Common Stock |
25,026 |
$187.53 |
Direct |
F11 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: